期刊档案 · Biochemistry, Genetics and Molecular Biology-Biotechnology
Biomaterials and Biosystems
ISSN 2666-5344 · Elsevier · United Kingdom
Biomaterials and Biosystems 完全开放获取，APC 约 2,390 美元，近 24 个月 43 篇文章投稿到接收中位 101 天，2025 年发文 21 篇，Scopus 收录。
研究范围
研究范围与定位
Biomaterials and Biosystems 由 Elsevier 出版。按 OpenAlex 近年发文统计，该刊主要发表 Tissue Engineering and Regenerative Medicine、Bone Tissue Engineering Materials、Cellular Mechanics and Interactions 等主题的论文，这 3 个主题约占 40%，主导子领域为 Biomaterials。（根据 OpenAlex 主题统计与中科院分区数据生成）
Biomaterials and Biosystems is the newest title in Elsevier's biomaterials science portfolio; it sits alongside Biomaterials, Materials Today Bio and Biomaterials Advances. Biomaterials and Biosystems is an interdisciplinary open access journal that publishes work at the nexus of engineering, chemistry, biology and medicine. The Journal covers the full spectrum of research, technology development and clinical translation of the biomedical engineering discipline. The Journal will effectively disseminate new knowledge, technologies, tools and discoveries in the field of human health and/or healthcare to the scientific community and to the wider community. The Journal commits to adhere to strict confidentiality agreements and affirms commitment to integrity and ethical conduct of the highest standard.Biomaterials and Biosystems selectively publishes manuscripts that:Deal with the development, assessment and application of the next generation of functional implantable devices that aspire to treat, augment or replace diseased and / or injured tissues, organs or functions of the body with their therapeutic capacity;Develop, assess and prove function of the next generation of biological systems that enable disease prevention, diagnosis, progression, monitoring, mitigation and treatment; andDiscuss ethical and social implications of educational, scientific, technological and clinical developments in the applied field of biomedical engineering.Indicative example of specific topics covered by Biomaterials and Biosystems include: Advanced Therapy Medicinal Products; Artificial Organs; Bioadhesives; Bioceramics; Bioelectronics; Bioengineering; Biofabrication; Biomechanics; Biomedical Engineering; Bionics; Biopolymers; Biosensors; Biotechnology; Cardiovascular Engineering; Cell Delivery; Cell Engineering; Clinical Trials; Developmental Engineering; Diagnostics; Differentiated Cells; Drug Delivery; Extracellular Matrix; Functionalised Biomaterials; Gene Delivery; Growth Factor Delivery; Hard Tissue Engineering; Hybrid Biomaterials; Imaging; Implants; Immune Response; Immunoengineering; In vitro models; In vivo models; Interfaces; Lab-on-Chip; Mechanobiology; Medical Devices; Modular Biomaterials; Molecular Engineering; Nanobiomaterials; Nanomedicine; Neural Engineering; Ophthalmic; Organ-on-Chip; Orthopaedics; Pluripotent Stem Cells; Regenerative Medicine; Self-assembly; Skeletal Engineering; Soft Tissue Engineering; Stem Cells; Synthetic Biology; Synthetic Polymers; Systems Biology; Tissue Engineering; Translational Medicine; Vaccines; Wound HealingBiomaterials and Biosystems accepts the following types of manuscripts:Research Communication: A hypothesis driven manuscript with at least detailed in vitro biological analysis and a maximum of 5 main display items (figures and tables). Additional display items (no limit) can be provided as supplementary information.Research Note: A hypothesis driven manuscript with at least detailed in vitro biological analysis and a maximum of 3 main display items (figures and tables). Additional display items (no limit) can be provided as supplementary information.Progress Report: An authoritative mini review (no more than 6,000 words, including tables, acknowledgements, references, etc.) with a maximum of 4 display items (figures and tables), which will provide a critical view / perspective of the subject in hand of the last 10 years. Authors should clearly demonstrate in their cover letter their relevant expertise in the topic of the manuscript.Review: An authoritative and educational in nature review (no more than 12,000 words, including tables, acknowledgements, references, etc.) with a maximum of 8 display items (figures and tables), which will provide a comprehensive literature review of the subject in hand. Authors should clearly demonstrate in their cover letter their relevant expertise in the topic of the manuscript.Leading Opinion: Invited opinionated papers about established and emerging research
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Biochemistry, Genetics and Molecular Biology-Biotechnology
主编 Dimitrios Zeugolis出版商官网
编委会国家分布：中国大陆 2 位（约 6%）；主要国家 德国 6、荷兰 5、爱尔兰 5、美国 3、中国 2（共 34 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Tissue Engineering and Regenerative MedicineMedicine18%
- Bone Tissue Engineering MaterialsEngineering14.3%
- Cellular Mechanics and InteractionsBiochemistry, Genetics and Molecular Biology7.8%
- 3D Printing in Biomedical ResearchEngineering7.4%
- Hydrogels: synthesis, properties, applicationsBiochemistry, Genetics and Molecular Biology6.9%
- Electrospun Nanofibers in Biomedical ApplicationsMaterials Science5.7%
- Nanoparticle-Based Drug DeliveryMaterials Science5.3%
- Wound Healing and TreatmentsMedicine3.3%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》（ 2026年3月发布）未收录
该期刊未被此版本分区表收录。
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
CiteScore 分区（Scopus，2026 年 6 月版）
| 学科 | 分区 | 排名 | 百分位 |
|---|---|---|---|
| Biochemistry | Q1 | 85/448 | 81% |
| Biomedical Engineering | Q1 | 84/342 | 75% |
| Biotechnology | Q2 | 82/325 | 74% |
| Biomaterials | Q2 | 45/146 | 69% |
Scopus 按 CiteScore 在每个学科内为期刊排名，百分位 75 及以上为 Q1，每 25 为一档；与中科院分区是不同体系。LetPub
数据库收录
ScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- CiteScore 2026-06
- 8.2LetPub ·
- CiteScore（出版商公布）
- 8.2出版商官网 ·
- SJR 2026-06
- 1.16LetPub ·
- SNIP 2026-06
- 0.99LetPub ·
- h-index
- 21OpenAlex ·
- i10-index
- 42OpenAlex ·
- 两年平均被引
- 5.57OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
逐年发文量 OpenAlex 统计 · 累计 136 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 27 | 27 | 309 |
| 2025 | 21 | 21 | 452 |
| 2024 | 15 | 15 | 375 |
| 2023 | 13 | 13 | 189 |
| 2022 | 32 | 32 | 92 |
| 2021 | 28 | 28 | 31 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
101 天投稿到接收中位数 · P25–P75 74 天 – 138 天
- 接收到上线
- 中位数 1 天（43 篇）
- 投稿到上线
- 中位数 101 天
- 样本
- 43 篇有投稿与接收日期的文章（窗口内共 44 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 24 WeeksLetPub ·
- 投稿到首次决定
- 1 天出版商官网 ·
- 外审后首次决定
- 40 天出版商官网 ·
- 投稿到接收
- 84 天出版商官网 ·
- 接收到发表
- 2 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 15 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 2,390 | 有 | CC BY、CC BY-NC、CC BY-NC-ND | |
| OpenAlex | USD 2,340 / EUR 2,190 / GBP 1,870 / JPY 290,230 | — | — | |
| LetPub | USD 2,000 | 有 | — | |
| 出版商官网 | USD 2,630 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
征稿中的专刊1 个，按截稿日期
出版商官网投稿准备要点7 项，摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- 1–7 个
- 正文篇幅
- ≤ 12,000 词
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- Highlights（研究亮点）
- 可选
- 图文摘要
- 可选
- 投稿信（Cover letter）
- 必须提供
接收的文章类型11 种，含篇幅限制
- hypothesisBiomaterials and Biosystems accepts the following types of manuscripts: Research Communication: A hypothesis driven manuscript with at least detailed in vitro b…未说明篇幅
- leading opinionLeading Opinion: Invited opinionated papers about established and emerging research topics, as well as relevant ethical, legal and societal issues.未说明篇幅
- letterBiomaterials and Biosystems accepts the following types of manuscripts: Research Communication: A hypothesis driven manuscript with at least detailed in vitro b…未说明篇幅
- literature reviewBiomaterials and Biosystems accepts the following types of manuscripts: Research Communication: A hypothesis driven manuscript with at least detailed in vitro b…未说明篇幅
- mini reviewBiomaterials and Biosystems accepts the following types of manuscripts: Research Communication: A hypothesis driven manuscript with at least detailed in vitro b…正文 ≤ 6,000 词
- opinionBiomaterials and Biosystems accepts the following types of manuscripts: Research Communication: A hypothesis driven manuscript with at least detailed in vitro b…未说明篇幅
- perspectiveBiomaterials and Biosystems accepts the following types of manuscripts: Research Communication: A hypothesis driven manuscript with at least detailed in vitro b…未说明篇幅
- progress reportProgress Report: An authoritative mini review (around 6,000 words, including references) with a maximum of 4 display items (figures and tables), which will prov…未说明篇幅
- research communicationResearch Communication: A hypothesis driven manuscript with at least detailed in vitro biological analysis and a maximum of 5 main display items (figures and ta…未说明篇幅
- research noteResearch Note: A hypothesis driven manuscript with at least detailed in vitro biological analysis and a maximum of 3 main display items (figures and tables).未说明篇幅
- reviewBiomaterials and Biosystems accepts the following types of manuscripts: Research Communication: A hypothesis driven manuscript with at least detailed in vitro b…正文 ≤ 12,000 词
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
作者在投稿时必须声明在稿件准备过程中使用生成式人工智能工具。 模型中文摘要
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
团体署名必须在投稿时于标题页声明，提交作者应在投稿系统的“Collaborative Author Groups”中列出该团体。 模型中文摘要
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
所有作者必须披露可能不当影响或偏袒其工作的财务和个人关系，并始终完成声明工具。 模型中文摘要
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 许可与版权 License options
作者将获得开放获取用户许可选项，建议在选择许可前审查这些选项及资助机构的许可要求。 模型中文摘要
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
原文 ↗出版商官网 ·- 开放获取 Open access
本刊引导作者参阅其开放获取信息页面以了解开放获取选项。 模型中文摘要
We refer you to our open access information page to learn about open access options for this journal.
原文 ↗出版商官网 ·- 同行评审 Peer review
本刊采用单盲同行评审，投稿先由编辑评估，通常至少送两名审稿人独立评审，录用与否由编辑决定。 模型中文摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
原文 ↗出版商官网 ·- 预印本 Preprints
作者可按Elsevier文章共享政策分享预印本，分享预印本不计为先前发表，本刊还提供SSRN免费预印本发布服务。 模型中文摘要
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Elsevier
- 出版国家或地区
- United Kingdom
- 出版语言
- English
- ISSN
- 2666-5344
- 官方链接
- 期刊主页 ↗DOAJ
- 投稿系统 ↗出版商官网
- 作者指南 ↗DOAJ
- Aims & Scope ↗DOAJ
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗DOAJ
- 查重政策 ↗DOAJ
常见问题
关于 Biomaterials and Biosystems 的常见问题
Biomaterials and Biosystems 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）43 篇已发表文章登记的日期，投稿到接收的中位数为 101 天（四分位 74–138 天）；投稿社区反馈的平均审稿速度为约 24 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Biomaterials and Biosystems 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 250 词；关键词：1–7 个；正文篇幅：≤ 12,000 词；参考文献格式：顺序编码制（按引用顺序编号）；Highlights：可选；图文摘要：可选；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Biomaterials and Biosystems 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 34 位编委中，中国大陆 2 位（约 6%）；人数最多的国家是 德国（6 位）、荷兰（5 位）、爱尔兰（5 位）。统计按编委会页面列出的机构国家计，仅供参考。
Biomaterials and Biosystems 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Biomaterials and Biosystems 被 Scopus、DOAJ 收录。
Biomaterials and Biosystems 是开放获取期刊吗？版面费多少？
Biomaterials and Biosystems 为完全开放获取。APC 约 2,390 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。